Humana Inc.

• Glenmark Pharmaceuticals has agreed to pay $7 million to settle antitrust lawsuits with three major healthcare entities - Humana, Centene, and Kaiser - over generic cholesterol medications Zetia and Vytorin. • The lawsuits alleged that Glenmark entered an anticompetitive agreement in 2010 with Schering Corporation and MSP Singapore Company LLC regarding patent infringement litigation for ezetimibe. • While reaching the settlement agreement, Glenmark explicitly denies all allegations and maintains the settlement does not indicate any admission of liability or illegal conduct.

• A comprehensive analysis of Medicare Part D claims reveals that CVS, Humana, Cigna, and UnitedHealth Group control 34.1% of all pharmacy spending, with even higher shares in specialty pharmacy segments. • Research demonstrates significant patient steering practices, with specialty drug claims being 19.8 percentage points more likely to be filled at insurer-PBM owned pharmacies than expected without steering. • The study highlights potential market competition concerns, particularly in specialty drug categories where insurer-PBM pharmacy control reaches up to 89.7% for certain therapeutic classes.

• The end of the Oncology Care Model has led to significant reductions in value-based care volumes, prompting concerns about sustaining extended patient services and equitable care delivery in oncology practices. • The Inflation Reduction Act's drug price negotiations could result in up to 49% reimbursement cuts for oncology providers, raising alarms about the financial sustainability of community practices. • Industry experts emphasize urgent need for pharmacy benefit manager (PBM) reform, calling for increased transparency and policy changes to address spread pricing and rebate schemes affecting biosimilar adoption.